Abstract
Background: Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system with onset in adults (age: 30–40 years). Irreversible functional disability occurs early, making MS the second most common cause of neurological disability in young adults. The World Health Organization described MS as one of the most socially costly disease, with an economic impact greater than Alzheimer’s disease and stroke. The aim of this work was to analyze the costs of patients with MS in a hospital in Northern Italy (Fidenza Hospital, Parma).
Methods: Data were collected in a retrospective, prevalence-based, observational study, conducted from a societal perspective. Patients (N = 100) were recruited via Fidenza Hospital and asked to fill a detailed questionnaire, asking for details on disease characteristics (type of disease, level of functional disability) and on all medical and non-medical resource consumption, and work capacity (sick-leaves and early retirement).
Results: Respondents mean age was 51.49 years. Up to 20% of patients had severe disease (Expanded Disability Status Scale [EDSS] score ≥ 7), 51% moderate disease (EDSS score 4–6.5) and 29% mild disease (EDSS < 4). The mean EDSS score in the sample was 5. The annual mean cost estimated for each patient was €16,926.74, of which 42.34% related to productivity losses (indirect costs), 39.32% to non-health direct costs and 28.34% to health direct costs.
Conclusions: Results, consistent with those of other studies, showed that MS is a relevant economic burden as related indirect costs are high.
Similar content being viewed by others
Bibliografia
Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444–52
http://allegati.aism.it/manager/UploadFile/2/libro%20bianco%20momento%20diagnosi.200954_16243.pdf
Smith SJ. The role of affect on the perception of disability in multiple sclerosis. Clin Rehabil 2000; 14: 50–4
Atlas: multiple sclerosis resources in the world (2008). www.who.int/entity/mental_health/neurology/Atlas_MS_WEB.pdf
Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000; 343: 939–52
Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Surg 2002; 104: 182–91
Grudzinski AN, Hakim Z, Cox ER, et al. The economics of multiple sclerosis. Distribution of costs and relationship to disease severity. Pharmacoeconomics 1999; 15: 229–40
Koopmanschap MA, Van Exel JN, Van Der Berg B, Brouwer WB. An overview of methods and applications to value informal care in economic evaluations of healthcare. Pharmacoeconomics 2008; 26: 269–80
Drummond FM, O’Brien B, Stoddart GI, Torrance GW. Methods for the Economic Evaluation in Health Care Programmes. New York: Oxford Medical Publications, 1997
Liljas B. How to calculate indirect cost in economic evaluations. Pharmacoeconomics 1988; 13: 1–7
Naci H, Fleurence R, Birt J, Duhig A. Economic burden of multiple sclerosis. Pharmacoeconomics 2010; 28: 363–79
Henriksson F, Johnsson B. The economic cost of multiple sclerosis in Sweden in 1994. Pharmacoeconomics 1998; 13: 597–606
Holmes BA, Madgwick T, Bates D. The cost of MS. Br J Med Econ 1995; 8: 181–93
Blumhardt L, Wood C. The economics of multiple sclerosis: a cost of illness study. Br J Med 1996; 10: 99–118
Carton H, Loos R, Pacolet J, et al. Utilisation and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium). J Neurol Neurosurg Psychiatry 1998; 64: 444–50
Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ 2006; 7 (Suppl. 2): S55–64
Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ 2006; 7 (Suppl. 2): S96–104
Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Sweden. Eur J Health Econ 2006; 7 (Suppl. 2): S75–85
Amato MP, Battaglia MA, Caputo D, et al. The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol 2002; 249: 152–63
Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ 2006; 7 (Suppl. 2): S45–54
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gori, F. Il costo del paziente affetto da sclerosi multipla: l’esperienza di un Centro specialistico del Nord Italia. G. Ital. Health Technol. Assess 4, 41–49 (2011). https://doi.org/10.1007/BF03320742
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03320742